Neurol. praxi. 2024;25(6):466-469 | DOI: 10.36290/neu.2024.073

Gepants - new moleculs in migraine treatment

MUDr. Petra Migaľová

Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika FN Ostrava

Migraine is a frequent disabling disease. The worldwide prevalence of migraine is estimated to be between 10-15 %. Migraines often start already in childhood, when the ratio of girls to boys tends to be higher in boys, and during puberty the numbers even out. As age continues, the ratio leans more towards the female sex. However, it mostly affects adults of working age, where women already significantly outnumber men. There are more than a million migrainers in the Czech Republic. Most of them suffer from episodic migraine, while at least twenty percent of them suffer from the chronic form, which significantly affects the quality of life of the patient and her/his family. In recent years, we have experienced a revolution in the treatment of migraine. We have available specific acute and prophylactic medication in various forms of administration.

Keywords: migraine, acute treatment, CGRP, gepants, rimegepant.

Received: October 13, 2024; Revised: October 31, 2024; Accepted: November 10, 2024; Prepublished online: November 10, 2024; Published: December 31, 2024  Show citation